<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165422</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-9DA</org_study_id>
    <nct_id>NCT03165422</nct_id>
  </id_info>
  <brief_title>A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan</brief_title>
  <official_title>A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a medical chart review of ipilimumab treatment after nivolumab treatment in melanoma
      in Japan
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">January 16, 2018</completion_date>
  <primary_completion_date type="Actual">January 16, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ipilimumab treatment after nivolumab treatment</measure>
    <time_frame>Approximately 19 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of nivolumab treatment after ipilimumab treatment</measure>
    <time_frame>Approximately 19 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of nivolumab treatment</measure>
    <time_frame>Approximately 19 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of ipilimumab treatment</measure>
    <time_frame>Approximately 19 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of interval between nivolumab treatment and ipilimumab treatment</measure>
    <time_frame>Approximately 19 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>Approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best overall response rate (BORR)</measure>
    <time_frame>Approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>Approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of treatment-related adverse events (AEs)</measure>
    <time_frame>Approximately 19 months</time_frame>
    <description>incidence of treatment-related adverse events (AEs)/adverse reactions (ARs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of treatment-related adverse events (AEs)</measure>
    <time_frame>Approximately 19 months</time_frame>
    <description>severity of treatment-related adverse events (AEs)/adverse reactions (ARs)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">68</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Adult patients with melanoma</arm_group_label>
    <description>Adult patients with melanoma at participating centers in Japan</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Adult patients with melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with melanoma who are patients at the participating centers in Japan will be
        enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt; 18 years of age or older

          -  Diagnosis of advanced melanoma (unresectable/metastatic), alive or deceased as of date
             of data collection

          -  Treated with ipilimumab between 31-Aug-2015 and 31-Mar-2017 before or after nivolumab
             treatment

        Exclusion Criteria:

          -  Patients enrolled in any clinical trials at any time

          -  Overlapping use of nivolumab and ipilimumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>1050001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

